News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TiGenix's Chondrocelect Available And Reimbursed In Belgium As Of May 1, 2011


4/29/2011 1:38:02 PM

Leuven (BELGIUM) - April 29, 2011 - TiGenix (NYSE EURONEXT: TIG) is pleased to announce that ChondroCelect®, its cell based medicinal product for cartilage repair in the knee, will be available and reimbursed for hospital use in Belgium with effect from May 1st 2011. ChondroCelect is the first cell-based product that obtained a centralized European Marketing Authorization as an Advanced Therapy Medicinal Product (ATMP). Belgium is now the first country to provide national reimbursement for an ATMP.

Read at BioSpace.com


comments powered by Disqus
TiGenix
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES